Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19710928 | 1.00 | LMNA (0.37) | LMNAGNAI3GNAO1GNAI1METAP1 | |
| SCHEMBL22355901 | 0.92 | SIGMAR1 (0.42) | EPHX1 | |
| SCHEMBL22355889 | 0.92 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL20747001 | 0.92 | SIGMAR1 (0.42) | EPHX1 | |
| SCHEMBL20794160 | 0.92 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL19605637 | 0.91 | MERTK (0.36) | LMNAMETAP1PLA2G2C | |
| SCHEMBL24704673 | 0.90 | SIGMAR1 (0.45) | EPHX1TSHR | |
| SCHEMBL11858592 | 0.90 | SIGMAR1 (0.45) | EPHX1TSHR | |
| SCHEMBL24704621 | 0.90 | SIGMAR1 (0.45) | EPHX1TSHR | |
| SCHEMBL19245329 | 0.90 | SIGMAR1 (0.45) | EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | LMNA 1389/4885GNAI3 442/4885GNAO1 215/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | LMNA 1389/4885GNAI3 442/4885GNAO1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.